Takeda announces biopharma venture for norovirus vax candidate

Japanese pharmaceutical company Takeda and US-based Frazier Healthcare Partners have announced a collaboration to launch HilleVax, Inc., a biopharmaceutical company to develop and commercialise Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialisation rights to its norovirus vaccine candidate, HIL-214 (formerly TAK214), worldwide outside of Japan, in exchange for upfront consideration, as well as future cash milestones and royalties on net sales. Takeda will retain commercialisation rights in Japan and HilleVax will integrate certain Japan development activities into its global development.